Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817063 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
A Phase 3 study of Eczema, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT00817063 is a Phase 3 study of Eczema that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 599 participants, above the 186-participant average among 29 other Eczema trials with a reported enrollment target (222% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00817063, a Phase 3 study of Eczema, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG alitretinoin
Study Locations (20)
California
- Shahram Jacobs, MD, Inc. - Encino
- University of California, San Diego Dermatology Clinical Trials Unit - La Jolla
- Dermatology Research Associates - Los Angeles
- Laser and Dermatology Center - Marina del Rey
- Integrated Research Group - Riverside
- University of California, Davis - Sacramento
- Therapeutics Clinical Research - San Diego
- East Bay Psoriasis Treatment Center - San Ramon
- Stanford University Dept of Dermatology - Stanford
- Solano Clinical Research, Dow Pharmaceutical Sciences - Vallejo
Arkansas
- Johnson Dermatology - Fort Smith
- Dermatology Research of Arkansas - Little Rock
- Hull Dermatology - Rogers
Colorado
- Longmont Clinic, P.C. - Longmont
- Western State Clinical Research Inc. - Wheat Ridge
Florida
- Park Avenue Dermatology, PA - Orange Park
- Palm Beach Research Center - West Palm Beach
Alabama
- University of Alabama, Birmingham - Birmingham
Arizona
- Radiant Research Inc. - Tucson
District of Columbia
- George Washington University - Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2009-01-08 |
| Est. Completion | 2012-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817063
The ClinicalTrials.gov registry entry for NCT00817063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 29 other Eczema trials with a reported enrollment target (222% higher). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00817063 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT00817063 about?
NCT00817063 is a clinical study titled "Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema". The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
What is the current status of trial NCT00817063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2009-01-08. Estimated completion is 2012-04-26.
What conditions does trial NCT00817063 study?
This clinical trial studies the following conditions: Eczema.
What interventions are being tested in trial NCT00817063?
The interventions under investigation include: Placebo (DRUG), alitretinoin (DRUG).
Who is sponsoring clinical trial NCT00817063?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00817063 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.